Major Drug Manufacturing Stocks With Highest Yields Researched By Dividend Yield - Stock, Capital, Investment. The major drug manufacturing industry is very interesting for dividend investors due to high yielding stocks. The great burdens within the industry are expected patent losses as well slowing growth. But prices for the most big drug companies are very attractive in relation to the risks. However, I screened the healthcare sector by the best-yielding major drug companies. Ten stocks remained of which five are yielding over four percent and seven are currently recommended to buy. One high yield is below the results.

Here are my favorite stocks:

AstraZeneca (AZN) has a market capitalization of $59.00 billion. The company employs 57,200 people, generates revenue of $33,591.00 million and has a net income of $10,016.00 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $14,792.00 million. The EBITDA margin is 44.04 percent (operating margin 38.09 percent and net profit margin 29.82 percent).

Financial Analysis: The total debt represents 17.66 percent of the company’s assets and the total debt in relation to the equity amounts to 40.13 percent. Due to the financial situation, a return on equity of 42.98 percent was realized. Twelve trailing months earnings per share reached a value of $6.24. Last fiscal year, the company paid $2.80 in form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 7.56, P/S ratio 1.75 and P/B ratio 2.60. Dividend Yield: 6.09 percent. The beta ratio is 0.64.

Eli Lilly & Co. (LLY) has a market capitalization of $50.90 billion. The company employs 38,440 people, generates revenue of $24,286.50 million and has a net income of $4,347.70 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $6,657.00 million. The EBITDA margin is 27.41 percent (operating margin 22.03 percent and net profit margin 17.90 percent).

Financial Analysis: The total debt represents 20.76 percent of the company’s assets and the total debt in relation to the equity amounts to 51.60 percent. Due to the financial situation, a return on equity of 33.49 percent was realized. Twelve trailing months earnings per share reached a value of $3.61. Last fiscal year, the company paid $1.96 in form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 12.15, P/S ratio 2.10 and P/B ratio 3.76. Dividend Yield: 4.45 percent. The beta ratio is 0.67.

Sanofi (SNY) has a market capitalization of $106.94 billion. The company employs 113,719 people, generates revenue of $43,131.85 million and has a net income of $5,984.18 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $12,589.66 million. The EBITDA margin is 29.19 percent (operating margin 16.18 percent and net profit margin 13.87 percent).

Financial Analysis: The total debt represents 15.41 percent of the company’s assets and the total debt in relation to the equity amounts to 27.46 percent. Due to the financial situation, a return on equity of 10.42 percent was realized. Twelve trailing months earnings per share reached a value of $2.99. Last fiscal year, the company paid $1.63 in form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 13.54, P/S ratio 2.50 and P/B ratio 1.56. Dividend Yield: 4.16 percent. The beta ratio is 0.91.

Bristol Myers Squibb (BMY) has a market capitalization of $59.77 billion. The company employs 27,000 people, generates revenue of $21,244.00 million and has a net income of $5,260.00 million. The firm’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $7,555.00 million. The EBITDA margin is 35.56 percent (operating margin 32.86 percent and net profit margin 24.76 percent).

Financial Analysis: The total debt represents 16.65 percent of the company’s assets and the total debt in relation to the equity amounts to 34.41 percent. Due to the financial situation, a return on equity of 23.37 percent was realized. Twelve trailing months earnings per share reached a value of $2.08. Last fiscal year, the company paid $1.33 in form of dividends to shareholders.

Market Valuation: Here are the price ratios of the company: The P/E ratio is 17.08, P/S ratio 2.81 and P/B ratio 3.76. Dividend Yield: 3.82 percent. The beta ratio is 0.45.

Take a closer look at the full table of the best yielding major drug manufacturing stocks. The average price to earnings ratio (P/E ratio) amounts to 16.71 and forward P/E ratio is 11.73. The dividend yield has a value of 4.17 percent. Price to book ratio is 3.60 and price to sales ratio 2.55. The operating margin amounts to 22.24 percent and the beta ratio is 0.60.

Related stock ticker symbols:
AZN, GSK, LLY, NVS, SNY, BMY, MRK, PFE, JNJ, ABT

Selected Articles:
· 12 Healthcare Dividend Stocks With Highest Short Ratio
· The Best Yielding Large Cap Healthcare Dividend Stocks
· 12 Healthcare Dividend Stocks With Gaining Earnings Momentum
· 7 Highly Profitable Healthcare Dividend Stocks With Great Yields

How Safe Are Your Dividends?

The most important thing for income investors is to make sure their dividends are safe. Check to see if your dividend stocks are also in the portfolios of investment Gurus.

Click Here to See the Top Guru Dividend Stocks

More Gurufocus Links

Latest Guru Picks	Value Strategies
Warren Buffett Portfolio	Ben Graham Net-Net
Real Time Picks	Buffett-Munger Screener
Aggregated Portfolio	Undervalued Predictable
ETFs, Options	Low P/S Companies
Insider Trends	10-Year Financials
52-Week Lows	Interactive Charts
Model Portfolios	DCF Calculator
RSS Feed	Monthly Newsletters
The All-In-One Screener	Portfolio Tracking Tool